X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

E&L Testing Market Growth To Be Driven By Single-Use Systems

Content Team by Content Team
30th January 2024
in Drug Development, News
FDA Solidifies Its Authority Over Laboratory-Developed Tests

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The worldwide extractable and leachable- E&L testing services market is all set to value $2.57 million by 2030, as per the latest report by ResearchAndMarkets. Between 2023 and 2030, this goes on to represent a CAGR of 15.13%, as the authors went on to state.

The report shared that because of the key role of such services for single-use systems as well as finished formulations, numerous analytical techniques, such as UPLC, Q-TOF, HPLC, FTIR, quickened the solvent extraction, and GC-TEA, are made use for extractable analysis.

Market growth elements

Pharmaceutical extractable & leachable (E&L) testing services

The heightened as well as growing demand when it comes to biopharmaceutical medicines has resulted in more demand when it comes to E&L testing in drug safety, like when mitigating cross-contamination risks, the report underscored.

As part of the development, the authors went on to note that this has gone on to drive the growth of single-use systems, which facilitate faster, more flexible creation and happen to be cost-effective solution. Critically, they also help lower cross-contamination risk, thereby elevating patient safety.

With the development of precise and custom E&L testing solutions, these must go on to meet regulatory requirements. This demand is an aspect within the anticipated expansion of the market, the research said.

A predictor of future progress

The E&L testing services market- 2022

It is well to be noted that in 2022, container closure systems as a container type, comprised of 31% of the E&L testing services market because of the long-term stability these systems go ahead and offer.

Moreover, the authors went on to cover the market share of drug product types within the E&L testing services market. They ascertained that orally inhaled as well as nasal drug products happened to have the highest share in the market in 2022. With high demand for novel drug delivery methods, this rate was found to be 41.88%.

It is worth noting that North America happened to be leading the E&L testing services market with a revenue share of 43.71% in 2022. This was evidently pushed by the players in the market that had innovative technologies and biopharmaceuticals, the data revealed.

As the expansion of the biopharmaceutical industry has gone on to continue, in 2022, rising demand for vaccine production helped the Asia Pacific region to witness quite prominent growth, with a CAGR of 15.32%, said the report.

The report, as such, forecasted that E&L testing services will go on to play a major role when it comes to making sure of the safety and quality of healthcare products, specifically up to 2030.

Previous Post

Largest Reorganization In History of FDA On Table In 2024

Next Post

Medicines For Europe Calls Simpler SPC Manufacturing Waiver

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post

Medicines For Europe Calls Simpler SPC Manufacturing Waiver

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In